Obsessed with Adam Strauss Hamilton Morris - The Secret Agenda To Block Psychedelic Therapy
Dec 23, 2024
Hamilton Morris, a prominent journalist and scientist known for his exploration of psychedelics in "Hamilton's Pharmacopeia," joins to unravel the shocking truth behind the FDA’s rejection of MDMA-assisted therapy. He reveals a covert agenda aimed at blocking this revolutionary treatment, highlighting the intertwining of politics, capitalism, and misinformation. The conversation dives into the misconceptions about safety concerns and the suppression of potentially life-changing therapies, emphasizing the urgent need for a reevaluation of how society approaches mental health solutions.
AI Snips
Chapters
Transcript
Episode notes
Compass Controversy
- Catherine McLean's criticism of Compass Pathways centered around their shift from nonprofit to for-profit.
- This sparked negative media coverage, raising concerns about corporate interests in psychedelics.
For-Profit Model
- Hamilton Morris argues that the for-profit model is essential for scaling psychedelic therapies.
- He emphasizes the high costs of clinical trials and the need for funding.
Active Placebo
- Hamilton Morris highlights the criticism MAPS received for a lack of an active placebo group in their MDMA trials.
- He explains that low-dose MDMA was anxiogenic, prioritizing patient well-being over perfect data.